Academy of Chinese Academy of Medical Sciences: my country has reached the clinical stage in the later stages of the research of malignant tumors

On the morning of August 25th, the National Health and Health Commission held a press conference. Jiang Jiandong, Dean of the Academy of Drugs of the Chinese Academy of Medical Sciences and the academician of the Chinese Academy of Engineering, introduced at the press conference that malignant tumors involved millions of households, which is a very fearful disease. In the past ten years, the major special projects of new drug creation have given a very important layout for malignant tumors, support more than 400 projects, and promote the listing of 31 new drugs.

Jiang Jiandong introduced that in the past, chemotherapy was greatly harmful in the treatment of tumors. After more than ten years of hard work, the side effects of the first country's targeted therapeutic medicine Akidinib have been reduced a lot. Zabitinib is not only used in China, but can already be exported to the United States. This field has made relatively obvious progress. It is a drug that ordinary people can use. Tenne drugs are also common anti -cancer drugs in Chinese hospitals. In terms of immunotherapy, there are PD-1 and PD-L1 drugs. After the launch of Tripley, my country began to target immunotherapy, which is also a very important progress. There are also ADC drugs combined with antibodies and compounds. Vidici Mipido is the first antibody coupling drug in my country. It is more targeted. In the past, there were no such drugs in my country. This is also a very important progress.

Jiang Jiandong introduced that the treatment of targeted therapy CAR-T is also immunotherapy, which makes clinical treatment more selectively. At present, the drugs under research have reached the stage of clinical comparison. Some drugs may make the side effects of tumor treatment smaller, patients with less pain, and new anti -cancer mechanisms. For breast cancer, lung cancer, cerebral gum tumor, lymphoma and other diseases, several drugs can be expected to serve Chinese patients in the next few years. (Reporter Shi Yingchun Liu Tingyu)

- END -